Abstract
INTRODUCTION
The key objective was to present a comprehensive analysis of the current diabetes market and its future direction to meet the unmet demands of diabetic consumers.
SCOPE OF STUDY
This report contains:
- Descriptions of diabetes therapeutics including drugs for diabetes and diabetes complications, diabetes diagnostics including blood glucose testing devices and supplies, and all other interventions
- The current global market status for diabetes therapeutics and diagnostics, with trends and forecasts for growth over the next 5 years
- Technological issues including the latest trends and a thorough patent analysis
- Discussion of predictions of a type II diabetes global epidemic
- Company profiles.
ANALYST CREDENTIALS
Ann Zhai was trained in oncology and is a registered patent agent with the United States Patent and Trademark Office. She has broad experience in business, capital markets, government regulation, and intellectual property law in the pharmaceutical, medical device, healthcare service, and consumer products industries.
Table of Contents
- Diabetes Therapies & Diagnostics: Global Markets
- Chapter 1 - SUMMARY
- SUMMARY TABLE: GLOBAL DIABETES MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ BILLIONS)
- SUMMARY FIGURE: GLOBAL DIABETES MARKET FORECAST BY SEGMENT, 2006-2013 ($ BILLIONS)
- Chapter 2 - OVERVIEW
- OVERVIEW
- TABLE 1 PREVALENCE OF TYPE I AND II DIABETES: TOP SIX COUNTRIES WITH HIGH GROWTH PROJECTIONS, THROUGH 2013 (MILLIONS)
- TABLE 2 PREVALENCE OF TYPE II DIABETES: TOP SIX COUNTRIES WITH PROJECTIONS, THROUGH 2013 (MILLIONS)
- TABLE 3 DEFINITIONS OF THE FOUR TYPES OF DIABETES
- TABLE 3 (CONTINUED)
- TABLE 4 SUMMARY OF DIABETES PRODUCTS AND APPLICATIONS
- Chapter 3 - DIABETES DISEASE
- CAUSATION, RISK FACTORS, AND COMPLICATIONS
- TABLE 5 CAUSAL OR RISK FACTORS BY DIABETES TYPE
- TABLE 6 COMPLICATIONS BY TYPE OF DIABETES
- DIABETES MANAGEMENT
- DIABETES MANAGEMENT (CONTINUED)
- DIABETES MANAGEMENT (CONTINUED)
- DIABETES MANAGEMENT
- Chapter 4 - DIABETES PRODUCT SEGMENTS
- CONTINUOUS GLUCOSE MONITORING SYSTEMS (CGMS)
- CONTINUOUS GLUCOSE MONITORING ý (CONTINUED)
- TABLE 7 FDA APPROVED CONTINUOUS GLUCOSE MONITORING SYSTEMS BY
MANUFACTURER
- INSULIN INFUSION PUMPS
- TABLE 8 FDA APPROVED INSULIN INFUSION PUMPS BY MANUFACTURER
- TABLE 9 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION PUMPS, THROUGH 2013 ($ MILLIONS)
- FIGURE 1 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING
SYSTEMS AND INSULIN INFUSION PUMPS, 2006-2013 ($ MILLIONS)
- INSULIN-DEPENDENT DRUGS
- TABLE 10 TECHNOLOGICAL EVOLUTION OF INSULIN DELIVERY METHODS
- TABLE 11 FDA APPROVED INSULIN-DEPENDENT PRODUCTS BY MARKET LEADER
- INSULIN-DEPENDENT DRUGS (CONTINUED)
- TABLE 12 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER, THROUGH 2013 ($ MILLIONS)
- FIGURE 2 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER,
2006-2013 ($ MILLIONS)
- INSULIN-INDEPENDENT DRUGS
- TABLE 13 THE SEVEN CLASSES OF TYPE II DIABETES DRUGS
- TABLE 13 (CONTINUED)
- SULFONYLUREAS
- TABLE 14 FDA APPROVED BRAND-NAME SULFONYLUREA DRUGS BY DRUGMAKER
- TABLE 14 (CONTINUED)
- BIGUANIDES
- TABLE 15 FDA APPROVED BRAND-NAME BIGUANIDE DRUGS
- ALPHA-GLUCOSIDASE INHIBITORS
- TABLE 16 FDA APPROVED BRAND-NAME ALPHA-GLUCOSIDASE INHIBITOR DRUGS
- MEGLITINIDES
- TABLE 17 FDA APPROVED BRAND-NAME MEGLITINIDE DRUGS
- TABLE 16 FDA APPROVED BRAND-NAME ALPHA-GLUCOSIDASE INHIBITOR DRUGS
- THIAZOLIDINEDIONES (TZD)
- TABLE 18 FDA APPROVED BRAND-NAME THIAZOLIDINEDIONES DRUGS
- INCRETIN MIMETICS
- TABLE 19 FDA APPROVED BRAND-NAME INCRETIN MIMETICS DRUGS
- DIPEPTIDYL PEPTIDASE 4 (DPP-4)
- TABLE 20 FDA APPROVED BRAND-NAME DPP-4 DRUGS
- TABLE 21 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST, THROUGH 2013 ($ MILLIONS)
- FIGURE 3 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST,
2006-2013 ($ MILLIONS)
- SURGICAL TREATMENT OF DIABETES
- TABLE 22 THE MARKET FOR NEW CLASSES OF DIABETES TREATMENTS
- TABLE 19 FDA APPROVED BRAND-NAME INCRETIN MIMETICS DRUGS
- Chapter 5 - DIABETIC COMPLICATIONS MARKET
- RETINOPATHY (EYE DISEASE)
- NEUROPATHY (NERVE DISEASE)
- NEPHROPATHY (KIDNEY DISEASE)
- ARTERIOSCLEROSIS (CARDIOVASCULAR DISEASE)
- OTHER COMPLICATIONS
- PRESCRIPTION DRUGS FOR DIABETES COMPLICATIONS
- CHOLESTEROL DRUGS
- Torcetrapib (Pfizer)
- HYPERTENSION DRUGS
- Exforge (Novartis)
- Tekturna (Novartis)
- CORONARY INTERVENTION
- Effient (Eli Lilly/Daiichi Sankyo)
- CHOLESTEROL DRUGS
- TABLE 23 DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS, BY MANUFACTURER
- TABLE 24 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, THROUGH 2013 ($ MILLIONS)
- FIGURE 4 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, 2006-2013 ($ MILLIONS)
- Chapter 6 - GENERIC ANTIDIABETIC DRUG MARKET
- GENERIC ANTIDIABETIC DRUG MARKET
- TABLE 25 FDA APPROVED GENERIC SULFONYLUREAS BY MANUFACTURER
- TABLE 25 (CONTINUED)
- TABLE 26 FDA APPROVED GENERIC BIGUANIDES BY MANUFACTURER
- TABLE 27 FDA APPROVED GENERIC MEGLITINIDES BY MANUFACTURER
- TABLE 28 FDA APPROVED GENERIC THIAZOLIDINEDIONES, BY MANUFACTURER
- TABLE 29 TOP SELLING GENERIC ANTIDIABETIC DRUG FORECAST, THROUGH 2013 ($ MILLIONS)
- Chapter 7 - DIABETES DRUGS IN DEVELOPMENT
- CLINICAL TRIALS PHASES I-IV
- PHASE I CLINICAL TRIALS ON DIABETES DRUGS
- TABLE 30 DIABETES DRUGS IN PHASE I CLINICAL TRIALS
- PHASE II CLINICAL TRIALS ON DIABETES DRUGS
- TABLE 31 DIABETES DRUGS IN PHASE II CLINICAL TRIALS
- PHASE III CLINICAL TRIALS ON DIABETES DRUGS
- TABLE 32 DIABETES DRUGS IN PHASE III CLINICAL TRIALS
- PHASE IV CLINICAL TRIALS ON DIABETES DRUGS
- TABLE 33 DIABETES DRUGS IN PHASE IV CLINICAL TRIALS
- COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS
- TABLE 34 COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS
- COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS
- TABLE 35 COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS
- COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPES OF DIABETES
- TABLE 36 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPE I
AND TYPE II DIABETES
- PHASE I CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
- TABLE 37 PHASE I CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC
COMPLICATIONS
- PHASE II CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
- TABLE 38 PHASE II CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC
COMPLICATIONS
- PHASE III CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
- TABLE 39 PHASE III CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON
DIABETIC COMPLICATIONS
- PHASE IV CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
- TABLE 40 PHASE IV CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
- COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
- TABLE 41 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON
DIABETIC COMPLICATIONS
- INCRETIN MIMETICS
- PRAMLINTIDE
- EXENATIDE
- LIRAGLUTIDE (PHASE III)
- DPP-4 INHIBITORS
- VILDAGLIPTIN
- SITAGLIPTIN
- GLITAZARS (DUAL-PPAR AGONISTS)
- MURAGLITAZAR
- CLINICAL TRIALS PHASES I-IV
- Chapter 8 - PATENT ANALYSIS OF DIAGNOSTIC AND THERAPEUTIC DIABETES
TREATMENTS
- TABLE 42 WORLDWIDE SHARES OF PATENTS AND PUBLISHED PATENT APPLICATIONS ON TYPE I AND TYPE II DIABETES TREATMENTS BY SELECTED COUNTRY, 1/1/2001-11/1/2007 (NUMBER)
- U.S. AND EUROPEAN PATENTS ON TYPE I DIABETES TREATMENTS
- TABLE 43 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE I DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
- U.S. AND EUROPEAN PATENTS ON TYPE II DIABETES TREATMENTS
- TABLE 44 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE II DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991 TO 11/30/2007 (NUMBER)
- TABLE 45 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
- TABLE 46 U.S. AND EUROPEAN SHARES OF PATENTS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
- TABLE 47 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SITAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
- TABLE 48 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON VILDAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
- TABLE 49 U.S. PATENT SHARES OF VILDAGLIPTIN BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
- TABLE 50 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SAXAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
- TABLE 51 U.S. PATENT SHARES OF LIRAGLUTIDE BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
- TABLE 52 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON TESAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
- TABLE 53 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON MURAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
- U.S. AND EUROPEAN PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS
METHODS
- TABLE 54 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS, 1/1/1991-11/30/2007 (NUMBER)
- U.S. AND EUROPEAN PATENTS ON INSULIN INFUSION PUMPS
- TABLE 55 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN INFUSION PUMPS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
- U.S. AND EUROPEAN PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS
- TABLE 56 U.S. AND EUROPEAN SHARES OF PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
- TABLE 57 U.S. AND EUROPEAN SHARES OF PATENTS ON BLOOD GLUCOSE METERS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
- Chapter 9 - INSULIN INHALER MARKET
- DRUGMAKERS DEVELOPING INHALABLE INSULIN
- PFIZER
- ABBOTT LABORATORIES AND KOS PHARMACEUTICALS
- ELI LILLY & CO. AND ALKERMES
- MANNKIND CORP.
- NOVO NORDISK AND ARADIGM
- BAXTER INTERNATIONAL
- NASTECH PHARMACEUTICAL CO.
- GENEREX BIOTECHNOLOGY
- TABLE 58 INHALED INSULIN PRODUCTS UNDER DEVELOPMENT BY COMPANY
- Chapter 10 - INSULIN INFUSION PUMP MARKET
- INSULIN INFUSION PUMP MARKET
- INSULIN INFUSION PUMP MARKET (CONTINUED)
- INSULIN INFUSION PUMP MARKET (CONTINUED)
- INSULIN INFUSION PUMP MARKET (CONTINUED)
- INSULIN INFUSION PUMP MARKET
- Chapter 11 - INSULIN DISPENSING PATCH MARKET
- INSULIN DISPENSING PATCH MARKET
- TABLE 59 INSULIN DISPENSING PATCHES BY MANUFACTURER
- Chapter 12 - COMPANY PROFILES
- ABBOTT LABORATORIES, INC.
- ABBOTT DIABETES CARE, INC.
- ACTAVIS
- ACTAVIS U.S.
- ALIZYME, PLC
- ALKERMES INC.
- ALKERMES INC. (CONTINUED)
- AMYLIN PHARMACEUTCIALS, INC.
- ARADIGM CORP.
- ASTELLA PHARMACEUTICALS
- ASTRAZENECA, PLC
- ASTRAZENECA U.S.
- AstraZeneca U.S. (Continued)
- ASTRAZENECA U.S.
- BARR PHARMACEUTICALS, INC.
- BARR PHARMACEUTICALS, INC. (CONTINUED)
- BAYER SCHERING PHARMA AG
- BAYER HEALTHCARE PHARMACEUTICALS U.S.
- BAYER GLOBAL HEALTHCARE DIABETES CARE
- Bayer Global HealthCare Diabetes Care (Continued)
- Bayer Global HealthCare Diabetes Care (Continued)
- BRISTOL-MYERS SQUIBB CO.
- BRISTOL-MYERS SQUIBB CO. (CONTINUED)
- CARACO PHARMA LABS, LTD.
- DAIICHI-SANKYO, LTD.
- DAIICHI-SANKYO, INC.
- Daiichi-Sankyo, Inc. (Continued)
- DEBIOTECH
- DEPOMED, INC.
- DEPOMED, INC. (CONTINUED)
- DEXCOM
- DR. REDDY' S LABORATORIES, LTD.
- DR. REDDY' S LABORATORIES, LTD.
- ELI LILLY & CO.
- ELI LILLY & CO. (CONTINUED)
- ELI LILLY & CO. (CONTINUED)
- ELI LILLY & CO. (CONTINUED)
- GLAXOSMITHKLINE, PLC
- GLAXOSMITHKLINE
- INSULET CORP.
- JOHNSON & JOHNSON CO.
- LIFESCAN, INC.
- KERYX BIOPHARMACEUTICALS INC.
- MANNKIND CORP.
- MANNKIND CORP. (CONTINUED)
- MEDTRONIC INC.
- MEDTRONIC DIABETES
- Medtronic Diabetes (Continued)
- MEDTRONIC DIABETES
- MERCK & CO., INC.
- MERCK & CO., INC. (CONTINUED)
- MYLAN, INC.
- NOVARTIS AG
- NOVARTIS U.S.
- Novartis U.S. (Continued)
- NOVARTIS U.S.
- NOVO NORDISK A/S
- NOVO NORDISK U.S.
- Novo Nordisk U.S. (Continued)
- PAR PHARMACEUTICAL COMPANIES, INC.
- PFIZER, INC.
- RANBAXY LABORATORIES, INC.
- RANBAXY U.S.
- ROCHE DIAGNOSTICS CORP.
- SANDOZ (NOVARTIS GENERIC DIVISION)
- SANDOZ U.S.
- SANOFI-AVENTIS A.G.
- SANOFI-AVENTIS U.S., LLC
- Sanofi-Aventis U.S., LLC (Continued)
- SANOFI-AVENTIS U.S., LLC
- SANTHERA PHARMACEUTICALS
- SMITHS MEDICAL
- SMITHS MEDICAL ASD, INC.
- TAKEDA PHARMACEUTICAL CO., LTD.
- TEVA PHARMACEUTICALS, INC.
- TEVA PHARMACEUTICALS USA
- WATSON LABORATORIES, INC.
- WYETH
- WYETH (CONTINUED)
- ABBOTT LABORATORIES, INC.
